Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 5/20 | 0.35 |
| ▸ | NOS1 | P29475 | 5/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993859 | 1.00 | HPGD (0.40) | HPGDNPSR1MAPTALDH1A1PLA2G1B | |
| SCHEMBL7940644 | 0.73 | NOTUM (0.38) | IDO1NOS1NOS3NOS2CYP1A2 | |
| SCHEMBL6760205 | 0.71 | HPGD (0.49) | HPGDNPSR1MAPTALDH1A1PLA2G1B | |
| SCHEMBL8780387 | 0.71 | HPGD (0.49) | HPGDNPSR1MAPTALDH1A1PLA2G1B | |
| SCHEMBL6760203 | 0.71 | HPGD (0.49) | HPGDNPSR1MAPTALDH1A1PLA2G1B | |
| SCHEMBL15606143 | 0.69 | CYP19A1 (0.45) | NOS1NOS2 | |
| SCHEMBL7943981 | 0.67 | BACE1 (0.36) | ALDH1A1IDO1NOS1NOS3NOS2 | |
| SCHEMBL7118738 | 0.62 | MAPT (0.43) | HPGDNPSR1MAPTALDH1A1PLA2G1B | |
| SCHEMBL13618175 | 0.62 | HPGD (0.53) | HPGDNPSR1MAPTALDH1A1PLA2G1B | |
| SCHEMBL7938886 | 0.62 | ESR1 (0.37) | ALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318416-B1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2318416-B1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2318416-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013794-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010013794-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | HPGD 927/4885NPSR1 1591/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.